Published in Cancer on February 01, 1994
Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity. Glycoconj J (2012) 0.87
Therapeutic radionuclides in nuclear medicine: current and future prospects. J Zhejiang Univ Sci B (2014) 0.76
Surgical immune interventions for solid malignancies. Am J Surg (2016) 0.75
The impact of agricultural soil erosion on the global carbon cycle. Science (2007) 3.74
Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours. Lancet (1982) 2.51
A monoclonal antibody that detects HLA-D region antigen in routinely fixed, wax embedded sections of normal and neoplastic lymphoid tissues. J Clin Pathol (1985) 2.00
Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol (1996) 1.91
Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol (1996) 1.91
RNA contacts subunits IIo and IIc in HeLa RNA polymerase II transcription complexes. J Biol Chem (1986) 1.80
Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication. J Nucl Med (1990) 1.76
Use of two epithelium-specific monoclonal antibodies for diagnosis of malignancy in serous effusions. Lancet (1982) 1.76
Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer (2002) 1.71
Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. J Clin Oncol (1990) 1.64
Surgical clips in planning the electron boost in breast cancer: a qualitative and quantitative evaluation. Int J Radiat Oncol Biol Phys (1996) 1.64
Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem (1984) 1.56
Positioning of two alpha subunit carboxy-terminal domains of RNA polymerase at promoters by two transcription factors. Proc Natl Acad Sci U S A (1997) 1.56
Transfer of oxygen from an artificial protease to peptide carbon during proteolysis. Proc Natl Acad Sci U S A (1991) 1.52
In vivo comparison of copper blood-pool agents: potential radiopharmaceuticals for use with copper-62. J Nucl Med (1991) 1.46
Restructuring of an RNA polymerase holoenzyme elongation complex by lambdoid phage Q proteins. Proc Natl Acad Sci U S A (2001) 1.45
Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol (1987) 1.42
Diffusion-enhanced fluorescence energy transfer. Annu Rev Biophys Bioeng (1982) 1.41
Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res (1986) 1.39
Alternative to toxicity and dosimetry of Y-90 labeled antibody. Int J Radiat Oncol Biol Phys (1989) 1.39
Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component. J Exp Med (1988) 1.34
Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent. Anal Biochem (1985) 1.33
Topography of transcription: path of the leading end of nascent RNA through the Escherichia coli transcription complex. Proc Natl Acad Sci U S A (1983) 1.32
Antibodies with infinite affinity. Proc Natl Acad Sci U S A (2001) 1.30
Copper-64-labeled antibodies for PET imaging. J Nucl Med (1992) 1.29
Antibodies against metal chelates. Nature (1985) 1.27
Management of the mature selected breech presentation: an analysis based on the intended method of delivery. Br J Obstet Gynaecol (1987) 1.27
Directed hydroxyl radical probing of 16S rRNA using Fe(II) tethered to ribosomal protein S4. Proc Natl Acad Sci U S A (1995) 1.27
Zinc is associated with the beta subunit of DNA-dependent RNA polymerase of Bacillus subtilis. Biochemistry (1977) 1.27
E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissues: correlation with histopathological grade, tumour stage and survival. Int J Cancer (1995) 1.25
Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res (1986) 1.24
Synthesis of the protein cutting reagent iron (S)-1-(p-bromoacetamidobenzyl)ethylenediaminetetraacetate and conjugation to cysteine side chains. Bioconjug Chem (1997) 1.22
Advances in pretargeting biotechnology. Biotechnol Adv (2001) 1.21
Indium-111-labeled autologous platelets for location of vascular thrombi in humans. J Nucl Med (1978) 1.21
RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. J Nucl Med (1995) 1.21
Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group. J Clin Oncol (1989) 1.20
Electrostatic field around cytochrome c: theory and energy transfer experiment. Proc Natl Acad Sci U S A (1990) 1.20
The two alpha subunits of Escherichia coli RNA polymerase are asymmetrically arranged and contact different halves of the DNA upstream element. Proc Natl Acad Sci U S A (1997) 1.19
An immunohistological study of testicular germ cell tumours using two different monoclonal antibodies against placental alkaline phosphatase. Br J Cancer (1984) 1.19
Indium-111 labelled monoclonal antibody to placental alkaline phosphatase in in the detection of neoplasms of testis, ovary, and cervix. Lancet (1985) 1.17
Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice. J Nucl Med (1988) 1.17
Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med (1988) 1.16
Mapping the sigma70 subunit contact sites on Escherichia coli RNA polymerase with a sigma70-conjugated chemical protease. Proc Natl Acad Sci U S A (1998) 1.16
Synthesis of a cleavable dinucleotide photoaffinity probe of ribonucleic acid polymerase: application to trinucleotide labeling of an Escherichia coli transcription complex. Biochemistry (1983) 1.16
A study of in vivo immune complex formation and clearance in man. J Immunol (1990) 1.14
Organization of open complexes at Escherichia coli promoters. Location of promoter DNA sites close to region 2.5 of the sigma70 subunit of RNA polymerase. J Biol Chem (1999) 1.13
Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J Nucl Med (1989) 1.13
Preparation, biodistribution and dosimetry of copper-64-labeled anti-colorectal carcinoma monoclonal antibody fragments 1A3-F(ab')2. J Nucl Med (1995) 1.13
Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology (2001) 1.12
Intraperitoneal radio-localization of tumors pre-targeted by biotinylated monoclonal antibodies. Int J Cancer (1990) 1.11
Antibody guided irradiation of brain glioma by arterial infusion of radioactive monoclonal antibody against epidermal growth factor receptor and blood group A antigen. Br Med J (Clin Res Ed) (1985) 1.11
Heavy metal contamination of roadside soils in the Greater Athens area. Environ Pollut (1987) 1.10
A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates. Cancer (1994) 1.09
Exploiting altered glycosylation patterns in cancer: progress and challenges in diagnosis and therapy. Trends Biotechnol (1994) 1.08
Preexisting human anti-murine immunoglobulin reactivity due to polyclonal rheumatoid factors. Cancer Res (1987) 1.07
Development of anti-idiotypic antibodies against tumour antigens and autoantigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies. Lancet (1988) 1.07
Positioning of sigma(S), the stationary phase sigma factor, in Escherichia coli RNA polymerase-promoter open complexes. EMBO J (1999) 1.07
Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res (1995) 1.06
Protein-protein interactions mapped by artificial proteases: where sigma factors bind to RNA polymerase. Trends Biochem Sci (2000) 1.05
Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci U S A (1997) 1.04
Antibody guided lymphangiography in the staging of cervical cancer. Br J Cancer (1985) 1.04
Binding of the sigma 70 protein to the core subunits of Escherichia coli RNA polymerase, studied by iron-EDTA protein footprinting. Proc Natl Acad Sci U S A (1996) 1.03
Selective binding of metal ions to macromolecules using bifunctional analogs of EDTA. J Med Chem (1974) 1.03
Palliation of obstructive nephropathy due to malignancy. Br J Urol (1995) 1.03
The use of indium-111-labeled leukocytes for abscess detection. Clin Nucl Med (1978) 1.02
Simplified method for conjugating macrocyclic bifunctional chelating agents to antibodies via 2-iminothiolane. Bioconjug Chem (1991) 1.02
Savings obtained by CA-125 measurements during therapy for ovarian carcinoma. The North Thames Ovary Group. Eur J Cancer (1992) 1.02
Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer. Lung Cancer (2009) 1.01
Mapping the promoter DNA sites proximal to conserved regions of sigma 70 in an Escherichia coli RNA polymerase-lacUV5 open promoter complex. Biochemistry (1998) 1.01
Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies. Int J Radiat Oncol Biol Phys (1989) 1.01
Serum stability of 67Cu chelates: comparison with 111In and 57Co. Int J Rad Appl Instrum B (1986) 1.00
Elevated expression of the interleukin 4 receptor in carcinoma: a target for immunotherapy? Br J Cancer (1989) 1.00
Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients. Nucl Med Biol (1999) 0.99
Diffusion-enhanced lanthanide energy-transfer study of DNA-bound cobalt(III) bleomycins: comparisons of accessibility and electrostatic potential with DNA complexes of ethidium and acridine orange. Biochemistry (1985) 0.99
Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry. Int J Cancer Suppl (1988) 0.98
Site-specific polysialylation of an antitumor single-chain Fv fragment. Bioconjug Chem (2009) 0.97
Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. J Clin Oncol (1997) 0.97
High dose cisplatin compared with high dose cyclophosphamide in the management of advanced epithelial ovarian cancer (FIGO stages III and IV): report from the North Thames Cooperative Group. Br Med J (Clin Res Ed) (1985) 0.97
Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med (1990) 0.97
Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer (1993) 0.97
Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study. Ann Oncol (2003) 0.96
Abdominal radical trachelectomy in West London. BJOG (2012) 0.95
Evaluation and selection of indicators for land degradation and desertification monitoring: methodological approach. Environ Manage (2014) 0.95
A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology (1999) 0.95
c-erbB-2 oncogene expression in ovarian cancer. J Pathol (1990) 0.95
Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group. Ann Oncol (1999) 0.95